Novosanis announced today it has closed a new round of financing. The share capital was increased by a combined effort from current investor Taste Invest and from the Novosanis management team. This new round brings the Flemish medical device company to a total in equity of 2 million euros.
“While healthcare costs are increasing worldwide the need for medical devices that bring more accuracy and enable early detection offer a significant benefit to patients outcome while bringing efficiency in diagnostics and therefore healthcare spending.” says Philip De Mulder, CEO Taste Invest NV.
Koen Beyers, CTO Novosanis, says “As a young start-up, Novosanis made significant progress and achieved major milestones since its foundation early 2013. The multidisciplinary team has now grown to 11 people. The previous rounds of seed funding combined with 3 innovation grants from VLAIO, an H2020 and INTERREG grant for Colli-PeeTM and VAX-IDTM device platforms have led to CE-IVD and FDA listing of the Colli-PeeTM device next to a recently finalized successful Phase 1 clinical trial with VAX-IDTM using Hepatitis B vaccine. ”
“Commercial sales of the Colli-PeeTM device is ramping up. The new funding round in combination with bank loans will enable further expansion and upscaling of Novosanis’ Colli-Pee device next to development and commercialization of the VAX-IDTM device platform. VAX-ID™ is suited for accurate drug delivery in the dermal layer of the skin and therefore offers new and unseen opportunities for healthcare organizations and pharmaceutical companies.” explains Vanessa Vankerckhoven, CEO Novosanis.
Read more about screaning for HPV in urine.